DARE missed EPS expectations by 19.49%
Mar 31, 2025, 10:34 PM
0.00%
What does DARE do
Dare Bioscience, a San Diego-based biopharmaceutical company focused on women's health, went public on April 10, 2014, and employs 23 staff. Its FDA-approved product, XACIATO, treats bacterial vaginosis, while its clinical and pre-clinical programs address various women's health issues.
Dare Bioscience (DARE) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Dare Bioscience's actual EPS was -$0.65, missing the estimate of -$0.54 per share, resulting in a -19.49% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.